ClouDr Group's (HKG:9955) diabetes-related digital drug product, ClouDT-01, was approved by China's Zhejiang Medical Products Administration and received a medical device registration
certificate.
ClouDT-01 is meant to be a complete diabetes management solution that benefits from artificial intelligence and real-time responses, according to a Thursday filing with the Hong Kong bourse.
The company's shares closed 8% higher on Thursday.
Price (HKD): $1.20, Change: $+0.090, Percent Change: +8.11%
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。